Suppr超能文献

接受度洛西汀治疗的抑郁患者中不同的细胞因子趋势是否表明存在不同的生物学背景。

Might different cytokine trends in depressed patients receiving duloxetine indicate differential biological backgrounds.

机构信息

Department of Formative Sciences, University of Catania, via Teatro Greco n.84, ZIP 95125, Catania, Italy.

出版信息

J Affect Disord. 2013 Mar 5;145(3):300-7. doi: 10.1016/j.jad.2012.08.007. Epub 2012 Sep 14.

Abstract

BACKGROUND

Correlational studies investigating neurohormonal-cytokine modulation by antidepressants suggest, among others, variations in cytokines balances as state markers of different biological subtypes of major depressive disorder (MDD) and response predictors to specific treatments. Objective of the study was to investigate cytokines modulation by duloxetine, a relatively newer SNRI with "clean" dual serotonin/norepinephrine mechanism.

METHODS

30 MDD patients and 32 healthy controls were assessed using Hamilton Depression Scale (HAM-D) and monitored for levels of IL-1β, IL-2, IL-4, IL-10, IL-12, IFN-γ and TNF-α, at baseline, week 6 and week 12 of duloxetine treatment (60mg/day) and at baseline, respectively.

RESULTS

Early responders (ER: defined at week 6 by reduction >50% of baseline HAM-D score) and early non-responders (ENR) showed opposite trends in cytokine levels during duloxetine treatment: ENR were characterized by baseline Th2 shift compared to controls (lower IL-1β, IFN-γ and TNF-α) with increase in Th1 cytokines levels during treatment (increase of IL-1β, IL-12, IFN-γ, IL-1β/IL-10 and TNF-α/IL-10, decrease of IL-10), achieving clinical response at week 12; ER were characterized by baseline Th2-to-Th1 relative switch compared to ENR (higher IL-1β, IL-1β/IL-10 and TNF-α/IL-10) with reduction in Th1 cytokines levels during treatment (decrease of TNF-α and TNF-α/IL-10), achieving clinical response at week 6.

LIMITATIONS

Small sample size.

CONCLUSIONS

In accordance to early clinical response, duloxetine treatment could divide depressed patients into at least 2 subgroups characterized by clinical and laboratory differentiated behavior, suggesting different neurobiological background within depressive syndrome differentially sensitive to different drug components: pro-serotonergic effect and increase in Th1 cytokines in ENR vs. pro-noradrenergic effect and decrease in Th1 cytokines in ER.

摘要

背景

通过对抗抑郁药的神经激素-细胞因子调节进行相关性研究,提示细胞因子平衡的变化可作为不同生物学亚型的重度抑郁症(MDD)的状态标志物,也可作为对特定治疗反应的预测因子。本研究旨在研究度洛西汀(一种新型的 SNRIs,具有“清洁”的双重 5-羟色胺/去甲肾上腺素机制)对细胞因子的调节作用。

方法

30 例 MDD 患者和 32 名健康对照者使用汉密尔顿抑郁量表(HAM-D)进行评估,并监测白细胞介素-1β(IL-1β)、白细胞介素-2(IL-2)、白细胞介素-4(IL-4)、白细胞介素-10(IL-10)、白细胞介素-12(IL-12)、干扰素-γ(IFN-γ)和肿瘤坏死因子-α(TNF-α)的水平,分别在基线、度洛西汀治疗 6 周和 12 周(60mg/天)以及基线时进行评估。

结果

早期应答者(ER:定义为第 6 周时 HAM-D 评分较基线降低>50%)和早期无应答者(ENR)在度洛西汀治疗期间表现出相反的细胞因子水平趋势:与对照组相比,ENR 在基线时表现出 Th2 偏移(IL-1β、IFN-γ 和 TNF-α 水平较低),治疗期间 Th1 细胞因子水平升高(IL-1β、IL-12、IFN-γ、IL-1β/IL-10 和 TNF-α/IL-10 升高,IL-10 降低),在第 12 周时达到临床应答;ER 与 ENR 相比,在基线时表现出 Th2 向 Th1 的相对转换(IL-1β、IL-1β/IL-10 和 TNF-α/IL-10 较高),治疗期间 Th1 细胞因子水平降低(TNF-α 和 TNF-α/IL-10 降低),在第 6 周时达到临床应答。

局限性

样本量小。

结论

根据早期临床反应,度洛西汀治疗可将抑郁患者分为至少 2 个亚组,这些亚组具有不同的临床和实验室行为特征,提示抑郁综合征内存在不同的神经生物学背景,对不同的药物成分具有不同的敏感性:ENR 中促 5-羟色胺能效应和 Th1 细胞因子增加,而 ER 中促去甲肾上腺素能效应和 Th1 细胞因子减少。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验